Anti-Myelin-Associated Glycoprotein Neuropathy: Development of a New Diagnostic Assay

• Unité de recherche: INNOSUISSE
• Numéro de projet: 13760.1;9 PFFLE-LS
• Titre du projet anglais: Anti-Myelin-Associated Glycoprotein Neuropathy: Development of a New Diagnostic Assay

Description succincte (Allemand)

Anti-Myelin-Associated Glycoprotein Neuropathy: Development of a New Diagnostic Assay

Description succincte (Anglais)

Anti-Myelin-Associated Glycoprotein Neuropathy: Development of a New Diagnostic Assay

Résumé des résultats (Abstract) (Allemand)

Anti-myelin-associated glycoprotein (MAG) neuropathy is a peripheral demyelinating neuropathy which is caused by IgM autoantibodies recognizing the carbohydrate epitope of MAG. The aim of this project is to chemically synthesize such epitope structures and to develop a new clinical test based on these MAG mimic epitopes to replace the existing BÜHLMANN anti-MAG ELISA based on a MAG antigen purified from human brains. The synthetic epitopes will also be combined with five different ganglioside epitopes (glycolipid structures) of the existing BÜHLMANN GanglioCombi® assay to generate a novel screening method suited for determining any peripheral neuropathies caused by autoantibodies to nerve structures. The simplified, automated production of microtiter plates and the development and validation of a software interpreting the results of this new Ganglio/MAG screening assay will complete the entire test package.

Résumé des résultats (Abstract) (Anglais)

Anti-myelin-associated glycoprotein (MAG) neuropathy is a peripheral demyelinating neuropathy which is caused by IgM autoantibodies recognizing the carbohydrate epitope of MAG. The aim of this project is to chemically synthesize such epitope structures and to develop a new clinical test based on these MAG mimic epitopes to replace the existing BÜHLMANN anti-MAG ELISA based on a MAG antigen purified from human brains. The synthetic epitopes will also be combined with five different ganglioside epitopes (glycolipid structures) of the existing BÜHLMANN GanglioCombi® assay to generate a novel screening method suited for determining any peripheral neuropathies caused by autoantibodies to nerve structures. The simplified, automated production of microtiter plates and the development and validation of a software interpreting the results of this new Ganglio/MAG screening assay will complete the entire test package.